Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Buy” by Analysts

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has been assigned an average rating of “Buy” from the five brokerages that are currently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $42.00.

A number of brokerages have recently commented on ORKA. BTIG Research reissued a “buy” rating and set a $56.00 price target on shares of Oruka Therapeutics in a research note on Monday. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research note on Monday, August 18th. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 12th.

Oruka Therapeutics Stock Up 3.0%

NASDAQ:ORKA opened at $19.18 on Friday. The stock’s 50-day simple moving average is $15.29 and its 200 day simple moving average is $12.58. The firm has a market capitalization of $718.29 million, a PE ratio of -6.83 and a beta of -0.29. Oruka Therapeutics has a twelve month low of $5.49 and a twelve month high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.02. On average, analysts anticipate that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ORKA. Jane Street Group LLC bought a new stake in Oruka Therapeutics in the fourth quarter worth approximately $343,000. Millennium Management LLC bought a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $588,000. Squarepoint Ops LLC purchased a new position in shares of Oruka Therapeutics during the fourth quarter valued at approximately $236,000. Toronto Dominion Bank purchased a new position in shares of Oruka Therapeutics during the fourth quarter valued at approximately $1,131,000. Finally, Wellington Management Group LLP boosted its position in shares of Oruka Therapeutics by 15.8% during the fourth quarter. Wellington Management Group LLP now owns 95,089 shares of the company’s stock valued at $1,844,000 after buying an additional 12,952 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.